Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Booly Protection Compound 15
2. Bpc 15
3. Bpc 157
4. Bpc-15
5. Bpc-157
1. Bpc-157
2. 137525-51-0
3. Bpc 157
4. Bepecin
5. Bpc 15
6. Pl-10
7. 8ed8nxk95p
8. Booly Protection Compound 15
9. Pld-116
10. Pl-14736
11. Gly-glu-pro-pro-pro-gly-lys-pro-ala-asp-asp-ala-gly-leu-val
12. Bpc157
13. Bpc15
14. Unii-8ed8nxk95p
15. Bpc-15
16. Chembl4297358
17. Ex-a4283
18. Mfcd06407962
19. Db11882
20. Bs-14984
21. D84081
22. Q27270252
23. Gastric Juice Peptide Fragment Trifluoroacetate (bpc 157) (h-gly-l-glu-l-pro-l-pro-l-pro-gly-l-lys-l-pro-l-ala-l-asp-l-asp-l-ala-gly-l-leu-l-val-oh)
24. L-valine, Glycyl-l-.alpha.-glutamyl-l-prolyl-l-prolyl-l-prolylglycyl-l-lysyl-l-prolyl-l-alanyl-l-.alpha.-aspartyl-l-.alpha.-aspartyl-l-alanylglycyl-l-leucyl-
| Molecular Weight | 1419.5 g/mol |
|---|---|
| Molecular Formula | C62H98N16O22 |
| XLogP3 | -9 |
| Hydrogen Bond Donor Count | 16 |
| Hydrogen Bond Acceptor Count | 24 |
| Rotatable Bond Count | 39 |
| Exact Mass | 1418.70415882 g/mol |
| Monoisotopic Mass | 1418.70415882 g/mol |
| Topological Polar Surface Area | 574 Ų |
| Heavy Atom Count | 100 |
| Formal Charge | 0 |
| Complexity | 3040 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 12 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
NDC Package Code : 73212-002
Start Marketing Date : 2020-08-01
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 71052-637
Start Marketing Date : 2019-07-08
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 71052-003
Start Marketing Date : 2023-11-29
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 84795-006
Start Marketing Date : 2025-11-13
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 84347-102
Start Marketing Date : 2025-02-17
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 85139-002
Start Marketing Date : 2025-01-15
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (100g/100g)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 83589-104
Start Marketing Date : 2025-04-30
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 87370-002
Start Marketing Date : 2026-01-12
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 85165-253
Start Marketing Date : 2025-10-15
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.
About the Company : Guizhou Utide Biotechnology Co., Ltd., based in Zunyi, Guizhou, is a specialized manufacturer of GLP-1 peptide APIs with 20,000 m² of manufacturing facilities. Backed by a core te...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Bepecin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Bpc-157,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Hospital Ángeles Tijuana
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 22, 2015
Lead Product(s) : Bpc-157,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Hospital Ángeles Tijuana
Deal Size : Inapplicable
Deal Type : Inapplicable
PCO-02 - Safety and Pharmacokinetics Trial
Details : Bepecin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 22, 2015
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
35
PharmaCompass offers a list of Bpc-157 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Bpc-157 manufacturer or Bpc-157 supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Bpc-157 manufacturer or Bpc-157 supplier.
A Bpc 157 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bpc 157, including repackagers and relabelers. The FDA regulates Bpc 157 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bpc 157 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Bpc 157 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Bpc 157 supplier is an individual or a company that provides Bpc 157 active pharmaceutical ingredient (API) or Bpc 157 finished formulations upon request. The Bpc 157 suppliers may include Bpc 157 API manufacturers, exporters, distributors and traders.
click here to find a list of Bpc 157 suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bpc 157 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Bpc 157 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Bpc 157 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Bpc 157 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Bpc 157 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Bpc 157 suppliers with NDC on PharmaCompass.
Bpc 157 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bpc 157 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Bpc 157 GMP manufacturer or Bpc 157 GMP API supplier for your needs.
A Bpc 157 CoA (Certificate of Analysis) is a formal document that attests to Bpc 157's compliance with Bpc 157 specifications and serves as a tool for batch-level quality control.
Bpc 157 CoA mostly includes findings from lab analyses of a specific batch. For each Bpc 157 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bpc 157 may be tested according to a variety of international standards, such as European Pharmacopoeia (Bpc 157 EP), Bpc 157 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bpc 157 USP).
